Novocure submitted a PMA application for its proprietary TTFields therapy, Optune Lua, targeting pancreatic cancer.
2 reports, 2 independent
Updated Aug 23
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Novocure submitted a PMA application for its proprietary TTFields therapy, Optune Lua, targeting pancreatic cancer.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Novocure (Jersey)
company in Saint Helier, Jersey
Nothing else this week.
- FDA
Coverage
Newest first; wire copies grouped- ZacksNVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer NovoCure Limited NVCR, on Wednesday, announced its submission of a premarket approval (PMA) application to the FDA for Tumor Treati
- Business WireNovocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer BAAR, Switzerland, August 20, 2025--(BUSINESS WIRE)--Novocure (NASDAQ: N